Preprint
TP53 mutation-associated immunosignatures impact on anti-PD-L1 treatment response in head and neck cancer patients.
Abstract
Background. Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant patients.
Methods. We analyzed the TCGA cohort of HNSCC patients in relation to their activation of 26 immune gene expression signatures, as well as their …
Authors
Sacconi A; Muti P; Pulito C; Pellini R; Strano S; Ben-David U; Bossi P; Blandino G
DOI
10.21203/rs.3.rs-2620802/v1
Preprint server
Research Square